All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Hydroxyl dendrimer
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Available
Deal Size: Not Available Upfront Cash: Not Available
Deal Type: Not Available November 02, 2020
Details:
Ashvattha has developed a novel hepatocyte targeted hydroxyl dendrimer therapeutic which enables selective targeting of farnesoid X receptor agonists on hepatocytes through the asialoglycoprotein receptor mediated uptake after systemic administration.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SRT-015
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: SRT-015
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Available
Deal Size: Not Available Upfront Cash: Not Available
Deal Type: Not Available November 02, 2020
Details:
Posters to highlight excellent efficacy of SRT-015 in NASH-relevant models, and comparator data with the ASK1 inhibitor selonsertib that is consistent with its lack of efficacy in phase 3 trials.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SZN-043
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: SZN-043
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $2.0 million Upfront Cash: $1.0 million
Deal Type: Funding October 15, 2020
Details:
SZN-043, is currently in preclinical development for severe alcoholic hepatitis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BOS-580
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BOS-580
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Boston Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 01, 2020
Details:
Under the terms of the agreement, Boston Pharmaceuticals will license worldwide development and commercial rights to the drug candidate BOS-580, for the treatment of Non-Alcoholic Steatohepatitis (NASH) from Novartis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ALT-801
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ALT-801
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2020
Details:
The Company believes the data provide clear validation of previously observed pharmacodynamic effects of ALT-801 and pave the way for the anticipated Phase 1 single and multiple ascending dose clinical trials following submission of a clinical trail application in Australia.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ALT-801
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ALT-801
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2020
Details:
ALT-801 demonstrated statistically superior reductions (p ≤ 0.05) in body weight, liver weight, plasma ALT, liver triglycerides and cholesterol, plasma cholesterol, NAFLD activity scores, and fibrosis markers compared to semaglutide.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TT-01025
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TT-01025
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: LG Chem
Deal Size: $350.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 18, 2020
Details:
Under the terms of the agreement, LG Chem will obtain exclusive worldwide rights, except Greater China region and Japan, to develop and commercialize TT-01025.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CM5480
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM5480
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: CalciMedica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 21, 2020
Details:
CalciMedica to use EpiPharma’s state-of-the-art Pre-clinical Drug Testing and Diagnostics Laboratory Platform to accelerate the discovery and development of CalciMedica’s CRAC channel inhibitor novel drug pipeline.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RABI-767
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: RABI-767
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $1.5 million Upfront Cash: Undisclosed
Deal Type: Funding July 14, 2020
Details:
The SBIR grant will be used for further development of company's lead therapeutic compound, RABI-767, a novel small molecule lipase inhibitor licensed from the Mayo Foundation for Medical Education and Research.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ACQT1127
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2020
Details:
The patent covers compounds that are intended to help patients with gout, NASH (nonalcoholic steatohepatitis), and other illnesses.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
